Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain

Jean M Delabar1,2, Marion Ortner3, Stephanie Simon4

  • 1INSERM U 1127, CNRS UMR 7225 UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et la Moelle épinière, ICM Sorbonne Universités Paris France.

Abstract

Insights

Plasma DYRK1A levels may help identify early Alzheimer's disease (AD) risk. Higher DYRK1A in cognitively impaired individuals suggests a blockage of age-related increases, potentially indicating early brain changes and amyloid beta pathology.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Aging Research

Background:

  • Effective Alzheimer's disease (AD) therapies are lacking, partly due to pre-symptomatic pathological changes.
  • Decreased plasma DYRK1A levels have been linked to mild cognitive impairment (MCI) and AD.
  • Aged mice exhibit elevated DYRK1A levels, suggesting an age-related DYRK1A increase.

Purpose of the Study:

  • To investigate DYRK1A levels in plasma of elderly individuals with varying cognitive status and brain amyloid load.
  • To determine if plasma DYRK1A can serve as a biomarker for early detection of amyloid beta pathology in memory complainers.

Main Methods:

  • Assessed DYRK1A levels in plasma from young/aged controls and elderly individuals reporting cognitive complaints.
  • Categorized elderly participants into low (L) and high (H) brain amyloid load groups.
  • Measured clusterin levels for comparison.

Main Results:

  • Human DYRK1A plasma levels increase with age.
  • Elderly individuals with high amyloid load (H group) showed DYRK1A levels similar to young adults, indicating a blocked age-associated increase.
  • Clusterin levels were comparable between L and H groups.

Conclusions:

  • Plasma DYRK1A levels reflect early brain changes associated with cognitive decline.
  • Plasma DYRK1A, unlike clusterin, shows potential as a biomarker for classifying elderly memory complainers at risk for amyloid beta pathology.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.8K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
126
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
152
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
417
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
645